BioPharmSignal logoBioPharmSignal

Biotech News

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Ascendis Pharma (ASND)Ascendis PharmaClinical readout

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation

Related news

ASNDAscendis Pharma2026-06-30 12:30 EST

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

ASNDAscendis Pharma2026-09-09 20:01 EST

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

View all latest news

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

ASNDAscendis Pharma2026-09-14 22:00 EST

Ascendis Announces Planned $400 Million Share Repurchase Program

ASNDAscendis Pharma2026-09-14 22:00 EST

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

ASNDAscendis Pharma2026-09-09 20:01 EST

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

ASNDAscendis Pharma2026-09-08 20:01 EST

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

ASNDAscendis Pharma2026-09-07 11:00 EST

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

Stock data

Close
239.04 USD
Market cap
13.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States